Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...

Jupiter Endovascular announced that it completed patient enrollment in the SPIRARE II pivotal clinical trial evaluating its Vertex system.

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ...

Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The biotech could be on the verge of expanding its lineup and entering a new era of growth.

China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...